Continuous interferon-alpha 2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients

Robert Roomer, Jilling Bergmann, Andre Boonstra, Bettina Hansen, Bart Haagmans, Sonja Kwadijk, Hanneke van Vuuren, Rob de Knegt, HLA Janssen

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

Background: Sustained virological response (SVR) rates in previous non-responders to pegylated interferon (PEG-IFN)-alpha and ribavirin for chronic HCV remain low (similar to 10%). We hypothesize that continuous subcutaneous delivery of fully potent interferon (IFN)-alpha 2b via an external pump will lead to stable blood concentrations and thereby prevent subtherapeutic trough levels associated with viral breakthrough. The aims of the study were to assess safety, tolerability and virological response in patients who were previous PEG-IFN-alpha/ribavirin non-responders. Methods: We randomized 30 HCV genotype 1 (n=24) and genotype 4 (n=6) patients to receive 6, 9 or 12 million units (MU) IFN-alpha 2b daily by continuous subcutaneous administration using an insulin pump (MiniMed (R) 508; Medtronic Inc., Minneapolis, MN, USA) in combination with ribavirin (1,000-1,600 mg) for 48 weeks. Results: The magnitude of viral decline in the 12 MU group after 4 weeks of treatment was 2.67 log HCV RNA compared with 1.21 and 1.27 log HCV RNA in the 9 and 6 MU groups, respectively (P=0.001). In the intention-to-treat analysis, the SVR rate was 20% (6/30). The per-protocol SVR rate was 25% (6/24), of which four out of six patients in the high-dose arm achieved SVR. Adverse events appeared dose-dependent, were mostly mild-to-moderate and were typical of IFN therapy. Five patients developed i Conclusions: Continuous delivery of IFN-alpha 2b can induce a strong dose-dependent viral suppression. This could be an effective approach in conjunction with, or as lead-in therapy prior to, treatment with a direct antiviral agent.
Original languageUndefined/Unknown
Pages (from-to)509-517
Number of pages9
JournalAntiviral Therapy
Volume17
Issue number3
DOIs
Publication statusPublished - 2012

Research programs

  • EMC MM-04-20-01
  • EMC MM-04-20-02-A
  • EMC MM-04-27-01
  • EMC OR-01-34-01

Cite this